NO20051351L - Genterapi for kritisk iskemi i lemmer med villtype eller mutante eNOS - Google Patents

Genterapi for kritisk iskemi i lemmer med villtype eller mutante eNOS

Info

Publication number
NO20051351L
NO20051351L NO20051351A NO20051351A NO20051351L NO 20051351 L NO20051351 L NO 20051351L NO 20051351 A NO20051351 A NO 20051351A NO 20051351 A NO20051351 A NO 20051351A NO 20051351 L NO20051351 L NO 20051351L
Authority
NO
Norway
Prior art keywords
enos
polypeptides
wild
limbs
type
Prior art date
Application number
NO20051351A
Other languages
English (en)
Norwegian (no)
Inventor
Katalin Kauser
Gabor Rubanyi
William P Dole
Hu Sheng Qian
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20051351L publication Critical patent/NO20051351L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • C12N9/0075—Nitric-oxide synthase (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
NO20051351A 2002-08-16 2005-03-15 Genterapi for kritisk iskemi i lemmer med villtype eller mutante eNOS NO20051351L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40363702P 2002-08-16 2002-08-16
PCT/US2003/025626 WO2004016761A2 (en) 2002-08-16 2003-08-15 Gene therapy for critical limb ischemia with wild type or mutant enos

Publications (1)

Publication Number Publication Date
NO20051351L true NO20051351L (no) 2005-04-28

Family

ID=31888259

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051351A NO20051351L (no) 2002-08-16 2005-03-15 Genterapi for kritisk iskemi i lemmer med villtype eller mutante eNOS

Country Status (15)

Country Link
US (1) US20040120930A1 (zh)
EP (1) EP1536689A4 (zh)
JP (1) JP2005539031A (zh)
KR (1) KR20050042162A (zh)
CN (2) CN100408101C (zh)
AU (1) AU2003263844A1 (zh)
BR (1) BR0313515A (zh)
CA (1) CA2494845A1 (zh)
IL (1) IL166362A0 (zh)
MX (1) MXPA05001763A (zh)
NO (1) NO20051351L (zh)
PL (1) PL375446A1 (zh)
RU (1) RU2005107414A (zh)
WO (1) WO2004016761A2 (zh)
ZA (1) ZA200502181B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014123749A1 (en) * 2013-01-30 2014-08-14 Board Of Regents Of The University Of Nebraska Compositions and methods for treating complications associated with diabetes
US20190284263A1 (en) * 2016-04-29 2019-09-19 Inovio Pharmaceuticals, Inc. In vivo use of chondroitinase and/or hyaluronidase to enhance delivery of an agent
CN105944243A (zh) * 2016-05-12 2016-09-21 段俊丽 一种eNOS表达与活化的调控装置及周围动脉疾病的治疗装置
CN107802826B (zh) * 2017-10-26 2020-02-18 首都医科大学宣武医院 eNOS突变体在促进血管生成中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU766238B2 (en) * 1998-03-09 2003-10-09 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for modulating vascularization
EP1016726A1 (en) * 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
IL145760A0 (en) * 1999-04-16 2002-07-25 Univ Yale eNOS MUTATIONS USEFUL FOR GENE THERAPY AND THERAPEUTIC SCREENING

Also Published As

Publication number Publication date
EP1536689A4 (en) 2006-09-06
WO2004016761A2 (en) 2004-02-26
CN1688197A (zh) 2005-10-26
WO2004016761A3 (en) 2005-03-17
PL375446A1 (en) 2005-11-28
JP2005539031A (ja) 2005-12-22
IL166362A0 (en) 2006-01-16
AU2003263844A1 (en) 2004-03-03
CN101391105A (zh) 2009-03-25
ZA200502181B (en) 2006-09-27
BR0313515A (pt) 2005-10-18
KR20050042162A (ko) 2005-05-04
US20040120930A1 (en) 2004-06-24
EP1536689A2 (en) 2005-06-08
RU2005107414A (ru) 2006-01-27
CA2494845A1 (en) 2004-02-26
MXPA05001763A (es) 2005-08-19
CN100408101C (zh) 2008-08-06

Similar Documents

Publication Publication Date Title
Nyström et al. Genetic consequences of a demographic bottleneck in the Scandinavian arctic fox
Samuk et al. Gene flow and selection interact to promote adaptive divergence in regions of low recombination
Glaser et al. The ConSurf‐HSSP database: the mapping of evolutionary conservation among homologs onto PDB structures
NO20051351L (no) Genterapi for kritisk iskemi i lemmer med villtype eller mutante eNOS
Paetkau et al. Genetic assignment methods for the direct, real‐time estimation of migration rate: a simulation‐based exploration of accuracy and power
Storz et al. The role of mutation bias in adaptive molecular evolution: insights from convergent changes in protein function
Valente et al. DYT13, a novel primary torsion dystonia locus, maps to chromosome 1p36. 13–36.32 in an Italian family with cranial‐cervical or upper limb onset
Kenkel et al. Evidence for a host role in thermotolerance divergence between populations of the mustard hill coral (P orites astreoides) from different reef environments
Evanno et al. Detecting the number of clusters of individuals using the software STRUCTURE: a simulation study
Petren et al. Comparative landscape genetics and the adaptive radiation of Darwin's finches: the role of peripheral isolation
Mona et al. Disentangling the effects of recombination, selection, and demography on the genetic variation at a major histocompatibility complex class II gene in the alpine chamois
Tang et al. Joint testing of genotype and ancestry association in admixed families
Luca et al. Multiple advantageous amino acid variants in the NAT2 gene in human populations
Ayyadevara et al. Lifespan extension in hypomorphic daf‐2 mutants of Caenorhabditis elegans is partially mediated by glutathione transferase CeGSTP2‐2
Poustka et al. On the origin of the chordate central nervous system: expression of onecut in the sea urchin embryo
DK1590467T3 (da) Anvendelse af regulatoriske sekvenser til specifik, transient ekspression i neuronalt bestemte celler
Sadrieh et al. Quantifying the origins of population variability in cardiac electrical activity through sensitivity analysis of the electrocardiogram
de Gruijter et al. Contrasting signals of positive selection in genes involved in human skin-color variation from tests based on SNP scans and resequencing
Nekrutenko et al. Oscillating evolution of a mammalian locus with overlapping reading frames: an XLαs/ALEX relay
Sy et al. Detection of kdr and ace-1 mutations in wild populations of Anopheles arabiensis and An. melas in a residual malaria transmission area of Senegal
Jons et al. Mutations in Conserved Amino Acids in the KCNQ1 Channel and Risk of Cardiac Events in Type‐1 Long‐QT Syndrome
Pérez‐Pereira et al. Prediction of fitness under different breeding designs in conservation programs
Witherspoon Selective constraints on P-element evolution.
Genick Structure-factor extrapolation using the scalar approximation: theory, applications and limitations
Jordan et al. Sequence and structural aspects of functional diversification in class I α-mannosidase evolution

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application